Last 1,903
Change Today 0.00 / 0.00%
Volume 0.0
As of 10:24 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

kamada ltd (KMDA) Snapshot

Open
$1,924
Previous Close
$1,912
Day High
$1,933
Day Low
$1,890
52 Week High
03/6/14 - $6,129
52 Week Low
11/25/14 - $1,160
Market Cap
684.9M
Average Volume 10 Days
121.4K
EPS TTM
$-0.35
Shares Outstanding
36.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAMADA LTD (KMDA)

kamada ltd (KMDA) Related Businessweek News

No Related Businessweek News Found

kamada ltd (KMDA) Details

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. Its respiratory disease products, including Glassia used in augmentation therapy for patients with emphysema secondary to congenital alpha-1 antitrypsin deficiency; and Bramitob to manage chronic pulmonary infection. The company’s immunoglobulin products include KamRAB for prophylaxis against rabies infection; KamRho(D)IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; Snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. In addition, it provides critical care products, such as Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of proper level in the patient’s blood plasma. Further, the company offers Heparin Lock Flush to maintain patency of indwelling IV catheter; Human Transferrin for diagnostic assays and cell cultures; and Kamacaine 0.5% used as anesthesia or analgesia for surgery, obstetrical procedures, and diagnostic and therapeutic procedures, as well as spinal anesthesia for surgery. Additionally, it offers coagulation factors, including Factor VIII, Factor IX, and Bupivacaine. The company also develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, chronic obstructive pulmonary disease, graft-versus-host diseases, and transplantations. It has a collaboration partnership with PARI and Baxter Healthcare Corporation. The company markets its products through strategic partners in the United States and Europe; and distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

Founded in 1990

kamada ltd (KMDA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $1.5M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $347.0K
Vice President of Operations and Plant Manage...
Total Annual Compensation: $232.0K
Vice President of Clinical Development & IP
Total Annual Compensation: $177.0K
Vice President of Research and Development
Total Annual Compensation: $199.0K
Compensation as of Fiscal Year 2013.

kamada ltd (KMDA) Key Developments

Kamada Ltd. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:10 PM

Kamada Ltd. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:10 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States.

Kamada Ltd. Reports Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Kamada Ltd. reported consolidated earnings results for the fourth quarter and year ended December 31, 2014. The company’s total revenues for the fourth quarter of 2014 of $25.8 million compare with $24.4 million for the fourth quarter of 2013.  Revenue from the proprietary products segment was $20.0 million compared with $9.1 million in the third quarter of this year and $18.6 million in the year-ago quarter, with the changes being primarily due to ordering patterns of Glassia from Baxter. For the fourth quarter of 2014, the Company reported operating income of $2.2 million compared with operating income of $2.4 million for the fourth quarter of 2013 and an operating loss of $2.5 million in the third quarter of 2014.  Net income for the fourth quarter of 2014 was $1.7 million or $0.05 per diluted share, compared with net income of $1.6 million or $0.04 per diluted share for the same period in 2013 and a net loss of $2.9 million or $0.09 per share in the third quarter of 2014.  Adjusted net income for the fourth quarter of 2014 was $2.4 million compared with adjusted net income of $2.0 million for the same period in 2013 and an adjusted net loss of $1.9 million in the third quarter of 2014. Adjusted EBITDA for the fourth quarter of 2014 was $3.6 million compared with $3.5 million for the fourth quarter of 2013 and negative $0.8 million in the third quarter of 2014. Net cash provided by operating activities was $699,000 against $4,012,000 a year ago. Purchase of property and equipment and intangible assets was $720,000 against $1,218,000 a year ago. Income before taxes on income was $1,727,000 against $1,560,000 a year ago. Adjusted net income was $2,421,000 against $1,963,000 a year ago. Total revenues for 2014 were $71.9 million, compared with $70.6 million for 2013.  Revenue in the Proprietary Products Segment was $45.2 million for the year, compared with $50.7 million for 2013, which included a $4.5 million milestone payment. 2014 revenue in the Distributed Product Segment increased 34% to $26.7 million from $20.0 million in 2013. Operating loss for 2014 of $10.9 million compares with operating income of $3.7 million for 2013.  Net loss for the 2014 year was $12.6 million or $0.35 per share, compared with net income of $0.5 million or $0.01 per diluted share for the prior year. Adjusted EBITDA for 2014 was negative $4.4 million, compared with positive $9.4 million for 2013. Net cash used in operating activities was $9,918,000 against $3,854,000 a year ago. Purchase of property and equipment and intangible assets was $3,076,000 against $5,643,000 a year ago. Loss before taxes on income was $12,583,000 against income before taxes on income of $467,000 a year ago. Adjusted net loss was $8,885,000 against adjusted net income of $3,156,000 a year ago.

Kamada Ltd. Affirms Sales Guidance for the Year Ended December 31, 2014

Kamada Ltd. affirmed sales guidance for the year ended December 31, 2014. The company affirms its previous guidance for total revenue for the year ended December 31, 2014 to be between $70 million and $72 million, with revenue from its Distribution Segment to be between $25 million and $26 million and revenue from its Proprietary Products Segment to be between $45 million and $47 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KMDA:IT 1,903.00 0.00

KMDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €36.67 EUR +0.90
View Industry Companies
 

Industry Analysis

KMDA

Industry Average

Valuation KMDA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAMADA LTD, please visit www.kamada.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.